Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection

Inclusion Criteria:

- Patients who have undergone hematopoietic cell transplant (HCT), solid organ
transplant (SOT)

- Have a primary or other severe immunodeficiency which predisposes to rapid
progression to disseminated AdV disease

- Must be able to ingest, absorb and tolerate oral medication

- Willing and able to understand and provide written informed consent. For minors or
those incapable of providing written informed consent (i.e., incapacitated),
understood, written and informed consent must be provided by a parent or legal
guardian or representative.

- To the best of his or her (or parent/guardian) knowledge, willing and able to
participate in all required study activities for the duration of the study.

Exclusion Criteria:

- Females who are pregnant or currently nursing.

- Patients with any other condition that would, in the judgment of the investigator,
put the patient at increased risk during participation in the study, or interfere
with the conduct of the study.